By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AVANIR Pharmaceuticals 

11388 Sorrento Valley Road

San Diego  California  92121  U.S.A.
Phone: 858-622-5200 Fax: 858-658-7447




Company News
AVANIR (AVNR) Announces U.S. Launch And Availability Of ONZETRA Xsail For The Acute Treatment Of Migraine In Adults 5/16/2016 7:23:36 AM
AVANIR (AVNR) To Present Data On NUEDEXTA And ONZETRA Xsail At American Academy of Neurology 2016 Annual Meeting 4/18/2016 8:41:07 AM
FDA Approves AVANIR (AVNR) New Migraine Treatment With Unique Inhalant Delivery System 1/29/2016 6:01:52 AM
AVANIR (AVNR) Taps New CEO with Commitment to Creating A Multi-Product CNS Company 1/26/2016 10:52:40 AM
AVANIR (AVNR) Names a New CEO 1/20/2016 6:43:04 AM
AVANIR Pharmaceuticals (AVNR) Announces Publication Of Study Evaluating The Prevalence Of Pseudobulbar Affect (PBA) Symptoms And Use Of Antipsychotic Medications In Nursing Homes 12/1/2015 6:48:54 AM
Concert Pharmaceuticals, Inc. (CNCE) Achieves $2 Million Milestone From AVANIR Pharmaceuticals (AVNR) For Phase III Initiation Of AVP-786 For Agitation In Patients With Alzheimer’s Disease 11/16/2015 10:17:47 AM
AVANIR Pharmaceuticals (AVNR) Announces Initiation Of Phase III Trial Of AVP-786 For Agitation In Patients With Alzheimer's Disease 11/16/2015 7:36:09 AM
AVANIR Pharmaceuticals (AVNR) Announces JAMA Publication Of Phase II Study Results Showing AVP-923 Significantly Reduced Agitation In Patients With Alzheimer's Disease 9/23/2015 11:07:18 AM
AVANIR Pharmaceuticals (AVNR) Prevails In NUEDEXTA Patent Appeal Maintaining Exclusivity Through 2026 8/11/2015 6:56:14 AM